Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
- A sponsored session will feature Dr.
Alex Hastie from Bionano, Dr.Suk See De Ravin fromNational Institute of Health (NIH) andTravis Hardcastle from Synthego presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applications
As part of a sponsored session titled “Optical Genome Mapping - Redefining Cell Line Genomic Integrity and Off-target Characterization,” three experts will share their experiences using OGM in their research, development and manufacturing processes. Presentations will cover OGM’s utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing. Dr.
A scientific poster by Dr.
Session | Title | Presenter | Presented | ||||||||||||
Sponsored Session |
Optical Genome Mapping - Redefining cell line genomic integrity and off-target characterization |
Hastie A., De Ravin S., Hardcastle T. |
Poster Number | Title | Author |
923 | Genome Integrity Assessment and Verification by Optical Genome Mapping for Cell Manufacturing/Bioprocessing Applications | Pang A. |
“We are excited to participate in ISSCR’s annual meeting and to see content that demonstrates OGM’s utility for pharmaceutical research and drug development. We believe that OGM can play a significant role in the development of new methods to analyze the quality of genome-edited cells, and welcome discussion of its incorporation into cell bioprocessing workflows, including stem cell therapy,” commented
More details on the conference can be found here: https://bionano.com/isscr2023/.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its
Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility in research, development, and manufacturing processes for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing, ; the utility of OGM for research in the areas reported in the presentations given and the posters made available at ISSCR’s annual meeting, and the growth and adoption of OGM for use in monitoring genomic integrity and off-target effects in cell lines. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, the impact of the COVID-19 pandemic and the ongoing
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
+1 (858) 888-7625
IR@bionano.com
Source: Bionano Genomics